Volume 27, Number 5—May 2021
Dispatch
Multisystem Inflammatory Syndrome in Children, Chile, May–August 2020
Table 2
Test | Median value (IQR) |
Reference range | |
---|---|---|---|
Emergency department | Intensive care unit | ||
Leukocytes, mm3 | 10,540.0 (7,400.0–15,900.0) | NA | 4,500–11,000 |
Lymphocytes, mm3 | 1,080.0 (732.5–2,579.5) | 560.5 (409.5–943.0) | 1,500–4,000 |
Platelets, mm3 | 175,000.0 (96,000.0–232,000.0) | 82,000.0 (40,000.0–111,250.0) | 150,000–400,000 |
Albumin, g/dL | 3.1 (2.9–3.4) | 2.2 (2.0–2.8) | 3.4–5.4 |
Troponins, ng/mL† | NA | 0.1 (0.0–1.8) | <0.034 |
Creatine phosphokinase, U/L | 133.5 (55.5–234.0) | 100.0 (162.5–220.5) | 32–294 |
Creatinine kinase-MB, U/L | 2.2 (1.1–11.9) | 3.3 (1.2–13.4) | <12 |
C-reactive protein, mg/L | 134.0 (94.0–300.5) | 198.5 (121.5–302.8) | <5 |
Procalcitonin, ng/mL† | NA | 13.0 (2.39–38.0) | <0.5 |
Ferritin, ng/mL | 206.5 (91.5–368.8) | 567.0 (304.5–1000.0) | 15–150 |
Triglycerides, mg/dL | 175.5 (103.0–244.5) | 205.5 (151.5–316.0) | <75 |
Lactate dehydrogenase, U/L | 288.0 (257.0–357.0) | 285.5 (261–328.3) | 105–333 |
Glutamic oxaloacetic transaminase, U/L | 45.0 (32.0–66.0) | 51.0 (36.5–66.0) | 0–40 |
Fibrinogen, mg/mL | 457.0 (375.0–513.0) | 447.0 (353.25–509.0) | 200–400 |
D-dimer, ng/mL | 1,700.0 (730.0–3,500.0) | 2,900.0 (1,670.0–3,950.0) | <500 |
Creatinine, mg/dL | 0.6 (0.4–1.2) | 0.8 (0.5–1.5) | Varies‡ |
Type B natriuretic pro-peptide, pg/mL§ | NA | 1,749.0 (255.8–4,722.8) | <125 |
Interleukin 6, g/mL¶ | NA | 322.0 (95.5–621.8) | <3.4 |
*Emergency department indicates value at admission; intensive care unit value indicates most severe value. IQR, interquartile range; NA, not available. †Troponins and procalcitonin were only measured in the intensive care unit. ‡Creatine reference ranges: <1 mo, 0.3–1.0 mg/dL; 1–12 mo, 0.2–0.4 mg/dL; 1–12 y, 0.3–0.7 mg/dL; >12 y, 0.5–1.1 mg/dL. §Only determined in 6 patients. ¶Only determined in 10 patients.
Page created: March 18, 2021
Page updated: April 22, 2021
Page reviewed: April 22, 2021
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.